| Cellbox Solutions–EU (govt): investment, 2024– equity investment up to €10m from EIC Accelerator |
2024-01-01 |
| Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth |
2023-09-25 |
| Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value |
2023-09-25 |
| Traceless Materials–GLS Bank: investment, 202309 financing round Series A totalling €36.6m incl new + co-investor GLS Bank Hamburg |
2023-09-25 |
| Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF |
2023-09-25 |
| Traceless Materials–Planet A: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor Planet A Ventures |
2023-09-25 |
| Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
| Traceless Materials–Sparkassen (DE): investment, 202309 financing round Series A totalling €36.6m incl new + co-investor HaSpa |
2023-09-25 |
| Traceless Materials–SWEN Capital Partners: investment, 202309 financing round Series A totalling €36.6m incl new + co-lead investor Blue Ocean fund |
2023-09-25 |
| Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG |
2023-09-25 |
| Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services |
2023-09-20 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| Broken String Biosciences–Holtzbrinck: investment, 202309 financing round Series A totalling $15m incl existing + co-investor DvH Ventures |
2023-09-18 |
| Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners |
2023-09-18 |
| SHS Capital–SEVERAL: investment, 202309 final closing of SHS VI fund adding ca €50 after first close bringing total fund size to €270m |
2023-09-13 |
| Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms |
2023-09-11 |
| Grande Bio-tech–Oncgnostics: molecular diagnostics, 202309 – distribution of early cancer detection tests developed by Oncgnostics in ASEAN countries |
2023-09-05 |
| Oncgnostics–Grande Bio-tech: investment, 202309 financing round totalling €7-digit incl lead investor Grande Bio-tech Co Ltd with €7-digit investment |
2023-09-05 |
| Oncgnostics–High-Tech Gründerfonds: investment, 202309 financing round totalling €7-digit incl existing + co-investor HTGF |
2023-09-05 |
| Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF |
2023-09-05 |
| Oncgnostics–Thuringia (govt): investment, 202309 financing round totalling €7-digit incl existing + co-investor bm-t |
2023-09-05 |
| Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms |
2023-08-25 |
| PhenomeX–Bruker: investment, 202308– acquisition cash tender offer $108m by Bruker at $1/share |
2023-08-17 |
| Bactolife–SEVERAL: investment, 202308 financing round Series A €30m led by Athos + incl Gates Foundation + Novo Holdings et al |
2023-08-08 |
| IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors |
2023-08-07 |
| AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
| Bind-X–Greeneering Invest: investment, 202308 financing round Series B totalling €10m incl new investor Greeneering Invest |
2023-08-01 |
| Bind-X–Heritage Group: investment, 202308 financing round Series B totalling €10m incl new investor HG Ventures |
2023-08-01 |
| Bind-X–High-Tech Gründerfonds: investment, 202308 existing investor HTGF |
2023-08-01 |
| Bind-X–K&K 1: investment, 202308 financing round Series B totalling €10m incl new investor K&K 1 |
2023-08-01 |
| Bind-X–Saxovent: investment, 202308 financing round Series B totalling €10m incl new investor Saxovent Smart Eco Investments |
2023-08-01 |
| Bind-X–SEVERAL: investment, 202308 financing round Series B €10m with HG Ventures + K&K1 + Greeneering Invest + Saxovent |
2023-08-01 |
| Bind-X–Vantage Value: investment, 202308 existing investor Vantage Value |
2023-08-01 |
| Cellbox Solutions–EU (govt): grant, 202308–202507 EIC Accelerator grant €2.5m |
2023-08-01 |
| Reata–Biogen: investment, 202307– acquisition $7.3b in cash by Biogen at $172.5/share ANNOUNCED |
2023-07-28 |
| AaviGen–Hopp Group: investment, 202307 financing round Series B €17m from existing investor DH-LT Investments GmbH |
2023-07-26 |
| Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech |
2023-07-24 |
| Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors |
2023-07-24 |
| Epigenomics–New Day Diagnostics: investment, 202307– acquisition of substantially all assets up to $12.05m plus license + milestones by New Day SIGNED |
2023-07-24 |
| Immatics–BMS: investment, 202307 private placement $35m with 2.42m ordinary shares at $14.461/share |
2023-07-24 |
| Roche–Alnylam: zilebesiran, 202307– collab $310m upfront + milestones developm + commerc in US w cost/profit sharing + excl ww outside US by Roche |
2023-07-24 |
| LimmaTech Biologics–Trophic Communications: public relations, 202307 service existent by Trophic |
2023-07-20 |
| Mage Biologics–SEVERAL: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| Mage Biologics–TVM: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| Mage Biologics–Zeria: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| TVM–MC Services: public relations, 202307 service existent by MC Services |
2023-07-20 |
| Pieris–Stifel: financial services, 202307– supply service Pieris retains Stifel Nicolaus as excl financial advisor to evaluate strategic options |
2023-07-18 |
| AATec Medical–SEVERAL: investment, 202307 seed financing round €2.7m from private investors + industry experts + family offices |
2023-07-17 |
| DTx Pharma–Novartis: investment, 202307 acquisition of DTx Pharma for $500m upfront + $500m milestones |
2023-07-17 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Vertama–BACB: investment, 202307 seed financing round totalling 7-digit € incl investor Berlin Angel Fund |
2023-07-12 |
| Vertama–High-Tech Gründerfonds: investment, 202307 seed financing round totalling 7-digit € incl lead investor HTGF |
2023-07-12 |
| Vertama–OTHER: investment, 202307 seed financing round totalling 7-digit € incl renowned business angels |
2023-07-12 |
| Vertama–SEVERAL: investment, 202307 seed financing round 7-digit € led by HTGF |
2023-07-12 |
| Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
| Celares–Biosynth: investment, 202307 acquisition of Celares by Biosynth |
2023-07-11 |
| Mallia Therapeutics–MC Services: public relations, 202307 service existent by MC Services |
2023-07-11 |
| Mallia Therapeutics–SEVERAL: investment, 202307c– seed financing round raising ongoing 7/23 |
2023-07-11 |
| BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target |
2023-07-10 |
| TolerogenixX–Akampion: public relations, 202307 service existent by Akampion |
2023-07-06 |
| TolerogenixX–Bruchmann Group: investment, 202307 financing round Series A 2nd closing totalling €7m incl new investor DB Speciality |
2023-07-06 |
| TolerogenixX–SEVERAL: investment, 202307 financing round Series A 2nd closing €7m bringing total round to €11.6m |
2023-07-06 |
| Zoetis–Numaferm: peptide technology, 202307– license + collab €na using peptein technology for RnD of veterinary therapeutics |
2023-07-06 |
| Acousia Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Cellbox Solutions–Akampion: public relations, 202307 service existent by Akampion |
2023-07-05 |
| inContAlert–SEVERAL: investment, 202307 pre-seed financing round €1.5m led by HTGF + Bayern Kapital + Carma Fund |
2023-07-01 |
| Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly |
2023-06-29 |
| Gleamer–Heal Capital: investment, 202306 financing round Series B totalling €27m incl new + co-lead investor Heal Capital |
2023-06-28 |
| Gleamer–SEVERAL: investment, 202306 financing round Series B €27m led by Supernova Invest + co-led by Heal Capital |
2023-06-28 |
| MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications |
2023-06-28 |
| Astraveus–Merck (DE): investment, 202306 seed financing round totalling €16.5m incl co-investor M Ventures |
2023-06-27 |
| Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners |
2023-06-27 |
| Docflix–SEVERAL: investment, 202306 seed financing round €2m led by HTGF + Brandenburg Kapital |
2023-06-27 |
| EBAMed–EFI Lake Geneva Ventures: investment, 202306 financing round Series A totalling €14.35m incl co-investor Efficient Frontier Investing |
2023-06-27 |
| EBAMed–EU (govt): investment, 202306 financing round Series A totalling €14.35m incl co-investor EIC Fund |
2023-06-27 |
| EBAMed–LIFIT Venture Capital Italia: investment, 202306 financing round Series A totalling €14.35m incl co-investor LIFIT |
2023-06-27 |
| EBAMed–Mayo Clinic: investment, 202306 financing round Series A totalling €14.35m incl existing + co-investor Mayo Clinic |
2023-06-27 |
| EBAMed–Occident: investment, 202306 financing round Series A totalling €14.35m incl co-investor Occident |
2023-06-27 |
| EBAMed–Panakès Partners: investment, 202306 financing round Series A totalling €14.35m incl lead investor Panakès Partners |
2023-06-27 |
| EBAMed–SEVERAL: investment, 202306 financing round Series A €14.35m led by Panakès Partners |
2023-06-27 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| MoonLake–SEVERAL: investment, 202306 public offering $400m+$60m with 8m+1.2m Class A ordinary shares at $50/share |
2023-06-26 |
| Lunaphore–Bio-Techne: investment, 202306– acquisition by of Lunaphore by Bio-Techne ANNOUNCED |
2023-06-22 |
| MESI–SHS Capital: investment, 202306 investment €18m by SHS in MESI |
2023-06-22 |
| Sanofi–SandboxAQ: AI-based drug discovery, 202306 collab existent disclosed of Sanofi with AQBioSim |
2023-06-22 |
| Tagworks Pharmaceuticals–Novartis: investment, 202306 financing round Series A totalling $65m incl co-investor Novartis Venture Fund |
2023-06-22 |
| Tagworks Pharmaceuticals–SEVERAL: investment, 202306 financing round Series A $65m led by Ysios Capital + Gilde Healthcare |
2023-06-22 |
| Pieris–Kendall Investor Relations: public relations, 202306 supply service existent IR by Kendall IR |
2023-06-21 |
| Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI |
2023-06-20 |
| Innovative Health Initiative–Philips: targeted cancer therapy, 202306– Philips is coordinating partner ot the IMAGIO project of IHI |
2023-06-20 |
| Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI |
2023-06-20 |
| Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI |
2023-06-20 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen |
2023-06-13 |
| Dynamic42–OTHER: investment, 202306 financing round Series A totalling mid-7-figure € incl a family office from the health sector |
2023-06-13 |
| Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office |
2023-06-13 |
| Dynamic42–Thuringia (govt): investment, 202306 financing round Series A totalling mid-7-figure € incl existing investor bm-t |
2023-06-13 |
| Chinook Therapeutics–Novartis: investment, 202306– acquisition $3.2b cash upfront + $300m cash milestones of Chinook by Novartis ANNOUNCED |
2023-06-12 |
| Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners |
2023-06-08 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
